



- - WEBCAST EVENT - -

Noonan/Russo's BioInvestor Forum

Friday 5 May 2001 from 15:00 BST

www.noonanrusso.com

With presentations from:

OXiGENE Inc

Presentation by Dr Bjorn Nordenvall, Chairman & CEO

Based in Stockholm and Boston, OXiGENE has a diverse portfolio of products to combat cancer and other major diseases. Their lead product, combrestatin, is the first in a new class of drugs – anti-tumour targeting agents – that starves tumours by shutting down their blood supply.

ProMetic Life Sciences Inc

Presentation by Pierre Laurin, President, Chairman & CEO

ProMetic, based in Quebec, owns proprietary enabling technology essential for use in therapeutics, large-scale drug purification, chemical genomics and proteomics, drug delivery and drug development.

LifePoint Inc

Presentation by Linda Masterson, CEO

Ontario-based LifePoint is developing the LifePoint™ Test System, a rapid, on-site diagnostic testing, screening and therapeutic drug monitoring device for initial use in law enforcement, workplace monitoring and emergency medical testing.

M&E Biotech A/S

Presentation by Søren Mouritsen, CEO and Jakob Schmidt, CFO

M&E Biotech, based in Copenhagen, has two distinct technology platforms – AutoVac™, a therapeutic vaccine or 'pharmaccine' technology for the treatment of serious chronic diseases associated with the overexpression of pathogenic self-proteins and cancers, and CellScreen™, a 'reverse genomics' technology that manipulates biological processes inside mammalian cells.

IsoTis NV

Clemens van Blitterswijk, CEO and Pieter Wolters, CFO

IsoTis, based in The Netherlands, aspires to become a global leader in the field of substitution medicine, fulfilling the need for human tissue and organ replacement with its hybrid technologies that are based on materials science, tissue engineering and biotechnology.

NeuroSearch A/S

Presentation by Jorgen Drejer, VP Drug Discovery Research Division and Henrik K Moltke, Director Investor Relations.

Copenhagen-based NeuroSearch is focused on the development of new drugs and procedures for the treatment of central nervous system (CNS) disorders, and has programmes in the areas of monoamines, ligated ion channels, voltage operated ion channels and neuronal survival factors.

The webcast will be available on Noonan/Russo's website until 30 July.

Individual presentations will also be available on company websites.